Sapropterin dihydrochloride for phenylketonuria

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 12, 2012, Pages

  Somaraju, Usha Rani ^a   Merrin, Marcus ^b  

^a Mallareddy Medical College for Women   (India)

^b AMERICAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLALANINE; PLACEBO; SAPROPTERIN; 5,6,7,8-TETRAHYDROBIOPTERIN; BIOPTERIN; DRUG DERIVATIVE; TETRAHYDROBIOPTERIN;

ABDOMINAL PAIN; BLOOD LEVEL; BONE PAIN; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEVER; GROWTH; HEADACHE; HUMAN; INTELLIGENCE TEST; NUTRITIONAL STATUS; PHENYLKETONURIA; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; SYSTEMATIC REVIEW; VOMITING; WECHSLER INTELLIGENCE SCALE; ADULT; BLOOD; CHILD; META ANALYSIS;

ADULT; BIOPTERIN; CHILD; HUMANS; PHENYLALANINE; PHENYLKETONURIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84874152368     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008005.pub3     Document Type: Review

References (49)

1. Lee P, Treacy EP, Crombez E, Wasserstein M, Waber L, Wolff J, et al.Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. American Journal of Medical Genetics. Part A 2008; Vol. 146A, issue 22:2851-9.
2. Levy H, Milanowski A, Chakrapani A, Cleary M, Trefz F, Whitley C, et al.A phase 3 study of the efficacy of sapropterin in reducing phe levels in subjects with phenylketonuria [abstract]. Journal of Inherited Metabolic Disease 2006;29(Suppl 1):13.
3. Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, et al.Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007;370(9586):504-10.
4. Trefz FK, Burton BK, Longo N, Casanova MM-P, Gruskin DJ, Dorenbaum A, et al.Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. Journal of Pediatrics 2009;154(5):700-7.
5. Nwose D. A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects. www.ClinicalTrials.gov [accessed 19 October 2012].
6. Gropmann AL. Neuroimaging and Neurocognitive Assessment and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria. www.ClinicalTrials.gov [accessed 19 October 2012]. [: NCT01412437]
7. Prasad S. Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients. www.ClinicalTrials.gov [accessed 19 October 2012].
8. Vincent C. Kuvan in Phenylketonuria (PKU) Patients Less Than 4 Years Old. www.ClinicalTrials.gov [accessed 19 October 2012].
9. Baulny HO, Abadie V, Feille F, Parscau L. Management of phenylketonuria and hyperphenylalaninemia. Journal of Nutrition 2007;137(6 Suppl 1):1561S-3S.
10. Belanger-Quintana A, Garcia MJ, Castro M, Desviat LR, Perez B, Mejia B, et al.Spanish BH4-responsive phenylalanine hydroxylase-deficient patients: evolution of seven patients on long-term treatment with tetrahydrobiopterin. Molecular Genetics and Metabolism 2005;86(Suppl 1):S61-6.
11. Bernegger C, Blau N. High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1919 patients observed from 1988 to 2002. Molecular Genetics and Metabolism 2002;77(4):304-13.
12. Blau N, Erlandsen H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Molecular Genetics and Metabolism 2004;82(2):101-11.
13. Boveda MD, Couce ML, Castineiras DE, Cocho JA, Perez B, Ugarte M, et al.The tetrahydrobiopterin loading test in 36 patients with hyperphenylalaninemia: evaluation of response and subsequent treatment. Journal of Inherited Metabolic Disease 2007;30(5):812.
14. Burlina A, Blau N. Effect of BH(4) supplementation on phenylalanine tolerance. Journal of Inherited Metabolic Disease 2009;32(1):40-5.
15. Burton BK, Grange DK, Milanowski G, Feillet F, Crombwz EA, Abadie V, et al.The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. Journal of Inherited Metabolic Disease 2007;30:700-7.
16. Cerone R, Schiaffino MC, Fantasia AR, Perfumo M, Birk Moller L, Blau N. Long-term follow-up of a patient with mild tetrahydrobiopterin-responsive phenylketonuria. Molecular Genetics and Metabolism 2004;81(2):137-9.
17. Channon S, Goodman G, Zlotowitz S, Mockler C, Lee PJ. Effects of dietary management of phenylketonuria on long-term cognitive outcome. Archives of Disease in Childhood 2007;92(3):213-8.
18. Cockburn F, Clark BJ. Recommendations for protein and amino acid intake in phenylketonuric patients. European Journal of Pediatrics 1996;155(Suppl 1):125-9.
19. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
20. Erlandsen H, Pey AL, Gamez A, Perez B, Desviat LR, Aguado C, et al.Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proceedings of National Academy of Science USA 2004;101(48):16903-8.
21. Fiege B, Bonafe L, Ballhausen D, Baumgartner M, Thony B, Meili D, et al.Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study. Molecular Genetics and Metabolism 2005;86(Suppl 1):S91-5.
22. Fiege B, Blau N. Assessment of tetrahydrobiopterin responsiveness in phenylketonuria. Journal of Pediatrics 2007;150(6):627-30.
23. Fiori L, Fiege B, Riva E, Giovanni M. Incidence of BH4-responsiveness in phenylalanine-hydroxylase-deficient Italian patients. Molecular Genetics and Metabolism 2005;86(Suppl 1):S67-74.
24. Giovanni M, Verduci E, Salvatici E, Fiori L. Phenylketonuria: Dietary and therapeutic challenges. Journal of Inherited Metabolic Disease 2007;30(2):145-52.
25. Hennermann JB, Buhrer C, Blau N, Vetter B, Monch E. Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Molecular Genetics and Metabolism 2005;86(Suppl 1):S86-90.
26. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
27. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
28. Koch R, Burton B, Hoganson G, Peterson R, Rhead W, Rouse B, et al.Phenylketonuria in adulthood: a collaborative study. Journal of Inherited Metabolic Disease 2002;25(5):333-46.
29. Kure S, Hou DC, Ohura T, Iwamoto H, Suzuki S, Sugiyama N, et al.Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Journal of Pediatrics 1999;135(3):375-8.
30. Leuzzi V, Carducci C, Carducci C, Chiarotti F, Artiola C, Giovanniello T, et al.The spectrum of phenylalanine variations under tetrahydrobiopterin load in subjects affected by phenylalanine hydroxylase deficiency. Journal of Inherited Metabolic Disease 2006;29(1):38-46.
31. Lindner M, Haas D, Zschocke J, Burgard P. Tetrahydrobiopterin responsiveness in phenylketonuria differs between patients with the same genotype. Molecular Genetics and Metabolism 2001;73(1):104-6.
32. Matalon R, Koch R, Michals-Matalon K, Mosley K, Stevens R. Tetrahydrobiopterin-responsive phenylalanine hydroxylase mutations. Journal of Inherited Metabolic Disease 2002;25(Suppl 1):23.
33. Matalon R, Michals-Matalon K, Koch R, Grady J, Tyring S, Stevens RC. Response of patients with phenylketonuria in the US to tetrahydrobiopterin. Molecular Genetics and Metabolism 2005;86(Suppl 1):S17-21.
34. Michals-Matalon K, Bhatia G, Guttler F, Tyring SK, Matalon R. Response of phenylketonuria to tetrahydrobiopterin. Journal of Nutrition 2007;137(6 Suppl 1):1564S-7S.
35. Medical Research Council (UK). Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. BMJ 1993;306(6870):115-9.
36. Muntau AC, Roschinger W, Habich M, Demmelmain H, Hoffmann B, Sommerhoff CP, et al.Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. New England Journal of Medicine 2002;347(26):2122-32.
37. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: phenylketonuria: screening and management. Pediatrics 2000;108(4):972-82.
38. Nuoffer JM, Thony B, Romstad A, Blau N. A patient with phenylketonuria successfully treated with tetrahydrobiopterin. Journal of Inherited Metabolic Disease 2001;24(Suppl 1):29.
39. Scriver CR, Seymour K. Hyperphenylalaninemia : Phenylalanine Hydroxylase Deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B editor(s). The Metabolic and Molecular Bases of Disease. 8th Edition. Vol. 2, New York: McGraw-Hill, 2001:1667-724.
40. Scriver CR. The PAH gene, phenylketonuria, and a paradigm shift. Human Mutation 2007;28(9):831-45.
41. Shintaku H, Kure S, Ohura T, Okano Y, Ohwada M, Sugiyama N, et al.Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene. Pediatric Research 2004;55(3):425-30.
42. Spaapen LJM, Bakker JA, Velter C, Loots W, Rubio ME, Forget PP, et al.Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency in Ditch neonates. Journal of Inherited Metabolic Disease 2001;24(3):325-58.
43. Steinfeld R, Kohlschutter A, Zschocke J, Lindner M, Ullrich K, Lukacs Z. Tetrahydrobipterin monotherapy for phenylketonuria patients with common mild mutations. European Journal of Pediatrics 2002;161(7):403-5.
44. Steinfeld R, Kohlschutter A, Ullrich K, Lukacs Z. A hypothesis on the biochemical mechanism of BH(4) -responsiveness in phenylalanine hydroxylase deficiency. Amino Acids 2003;25(1):63-8.
45. Steinfeld R, Kohlschutter A, Ullrich K, Lukacs Z. Efficiency of long-term tetrahydrobiopterin monotherapy in phenylketonuria. Journal of Inherited Metabolic Disease 2004;27(4):449-53.
46. Trefz FK, Aulehla-Scholz C, Blau N. Successful treatment of phenylketonuria with tetrahydrobiopterin. European Journal of Pediatrics 2001;160(5):315.
47. Wappner R, Cho S, Kronmal RA, Schuett V, Seashore MR. Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors. Pediatrics 1999;104(6):e68.
48. Williams RA, Mamotte CDS, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. Clinical Biochemist Reviews 2008;29(1):31-41.
49. Somaraju UR, Merrin M. Sapropterin dihydrochloride for phenylketonuria. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD008005.pub2]